Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | BMC Medicine

Fig. 2

From: Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial

Fig. 2

Parasitemia following homologous and heterologous challenge infection. The percentage of volunteers remaining qPCR negative (Kaplan–Meier survival proportions) after challenge infection with a homologous NF54 (n = 5 immunized; n = 5 controls) (a) or heterologous NF135.C10 (n = 10 immunized; n = 5 controls) (b) or NF166.C8 (n = 9 immunized; n = 5 controls) (c) strain is shown. Solid lines represent CPS-immunized volunteers and dotted lines represent placebo control-immunized volunteers. ** P < 0.01 as determined by Log-rank (Mantel Cox) test

Back to article page